

## Article

## Synergy between Synthetic Antimicrobial Polymer and Antibiotics: A Promising Platform to Combat Multidrug-resistant Bacteria

Rashin Namivandi-Zangeneh, Zahra Sadrearhami, Debarun Dutta, Mark Willcox, Edgar H. H. Wong, and Cyrille Boyer

ACS Infect. Dis., **Just Accepted Manuscript** • DOI: 10.1021/acsinfecdis.9b00049 • Publication Date (Web): 02 Apr 2019

Downloaded from <http://pubs.acs.org> on April 9, 2019

### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

# Synergy between Synthetic Antimicrobial Polymer and Antibiotics: A Promising Platform to Combat Multidrug-resistant Bacteria

Rashin Namivandi-Zangeneh,<sup>†</sup> Zahra Sadrearhami,<sup>†</sup> Debarun Dutta,<sup>‡</sup> Mark Willcox,<sup>‡</sup> Edgar Wong,<sup>\*,†</sup> and Cyrille Boyer<sup>\*,†</sup>

<sup>†</sup>*Centre for Advanced Macromolecular Design (CAMD) and Australian Centre for NanoMedicine (ACN), School of Chemical Engineering, Building E8, Gate 2, High Street, University of New South Wales – Sydney, Sydney (Kensington), 2052, NSW, Australia; Emails: [edgar.wong@unsw.edu.au](mailto:edgar.wong@unsw.edu.au), +61 2 9385 5268; Fax: +61 2 9385 5966; [cboyer@unsw.edu.au](mailto:cboyer@unsw.edu.au); Phone: +61 2 9385 5268; Fax: +61 2 9385 5966*

<sup>‡</sup>*School of Optometry and Vision Science, Rupert Myers Building, Gate 13, High Street, University of New South Wales – Sydney, Sydney (Kensington), 2052, NSW, Australia, Phone: +61 2 9385 4164; Fax: +61 2 9313 6243*

The failure of many antibiotics in the treatment of chronic infections caused by multidrug-resistant (MDR) bacteria necessitates the development of effective strategies to combat this global healthcare issue. Here, we report an antimicrobial platform based on the synergistic action between commercially available antibiotics and a potent synthetic antimicrobial polymer that consists of three key functionalities – low-fouling oligoethylene glycol, hydrophobic ethylhexyl and cationic primary amine groups. Checkerboard assays with *Pseudomonas aeruginosa* and *Escherichia coli* demonstrated synergy between our synthetic antimicrobial polymer and two antibiotics, doxycycline and colistin. Co-administration of these compounds significantly improved the bacteriostatic efficacy especially against MDR *P. aeruginosa* strains PA32 and PA37, where the minimal inhibitory concentrations (MICs) of polymer and antibiotics were reduced by at least 4-fold. A synergistic killing activity was observed when the antimicrobial polymer was used in combination with doxycycline, killing > 99.999% of planktonic and biofilm *P. aeruginosa* PAO1 upon 20 min treatment at polymer concentration of 128  $\mu\text{g mL}^{-1}$  (4.6  $\mu\text{M}$ ) and doxycycline concentration of 64  $\mu\text{g mL}^{-1}$  (133.1  $\mu\text{M}$ ). In addition, this synergistic combination reduced the rate of resistance development in *P. aeruginosa* compared to individual compounds, and was also capable of reviving susceptibility to treatment in the resistant strains.

**KEYWORDS:** *combination therapy, antibiotic resistance, antimicrobial polymers, RAFT polymerization, biofilm*


The rising number of infections caused by multidrug-resistant (MDR) bacteria is a critical global healthcare concern.<sup>1-5</sup> Although resistance development is a natural phenomenon, the extensive overuse of antibiotics has accelerated the process in bacteria over the past few decades.<sup>6-9</sup> As a result, the efficiency of many antibiotics has diminished, causing longer hospital stays, higher medical costs and increased mortality.<sup>10, 11</sup> To address this global issue, more effective therapeutic approaches are required. These include improving the efficiency of current antibiotics through chemical modification or using adjuvants,<sup>12-15</sup> employing antimicrobial agents with novel cellular targets,<sup>16-21</sup> and applying combination therapy over monotherapy<sup>22, 23</sup>.

In combination therapy, the co-administration of traditional antibiotics along with other antibiotics<sup>24-26</sup> or non-antibiotic drugs<sup>27, 28</sup> has been reported to improve treatment efficiency compared to using individual compounds. Furthermore, combination therapy not only hinders resistance development but also revives MDR bacteria's susceptibility to treatment.<sup>11, 29</sup> Additionally, synergistic combinations can effectively reduce the required treatment dose and possible side effects.<sup>30</sup> However, to achieve synergistic activity, compound pairings need to be selected rationally. A recent report on combination therapy shows that indifference or antagonism is more likely to occur than synergism.<sup>31</sup> Although many reports have been published on combination therapy using common antibiotics and drugs, only a few studies have focused upon using synthetic antimicrobial polymers in combination with antibiotics.<sup>32-34</sup>

By mimicking the fundamental composition of natural antimicrobial peptides, synthetic antimicrobial polymers have recently emerged as potential antimicrobial agents that target the bacteria cell membrane.<sup>16, 17</sup> Generally, electrostatic interactions between the cationic residues of antimicrobial polymers and the anionic components of bacteria cell walls or outer membranes is the first step in bactericidal activity, followed by the insertion of the polymer hydrophobic sub-units into the cytoplasmic membrane to induce membrane disruption/permeabilization leading to cell death. Such a bactericidal mechanism hinders resistance development in bacteria, thereby making synthetic antimicrobial polymers a promising co-agent in combination therapy to create more potent antimicrobial strategies.

On the basis of our experience in the development of antimicrobial polymers<sup>35-37</sup> and the potential benefits of combination therapy,<sup>38-41</sup> we herein investigate the efficacy of an antimicrobial platform based on our

lead synthetic antimicrobial polymer<sup>35, 39</sup> in combination with different classes of commercially available antibiotics (e.g., doxycycline from the tetracycline family, as depicted in **Figure 1**). The potency of these combinations is investigated via checkerboard assay and the synergistic combinations are further studied in terms of bactericidal activity and resistance development in bacteria.



**Figure 1.** Synergistic antibacterial activity of synthetic antimicrobial polymer and doxycycline.

## Materials and methods

**Materials.** Ethylenediamine (Sigma-Aldrich,  $\geq 99\%$ ), di-*tert*-butyl dicarbonate (Aldrich, 99%), triethylamine (Scharlau, 99%), acryloyl chloride (Merck,  $\geq 96\%$ ), oligoethylene glycol methyl ether acrylate (OEGA)  $M_n$  480 g mol<sup>-1</sup> (Aldrich), 2-ethylhexyl acrylate (Aldrich, 98%), trifluoroacetic acid (TFA) (Sigma-Aldrich, 99%), hexane (Merck), diethyl ether (Merck), 1,4-dioxane (Merck) and basic alumina (Al<sub>2</sub>O<sub>3</sub>) (LabChem) were used as received. 2,2'-azobis (2-methylpropionitrile) (AIBN) (Acros, 98%) was purified by recrystallization from methanol. Sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>), magnesium sulfate (MgSO<sub>4</sub>), sodium hydrogen carbonate (NaHCO<sub>3</sub>), tetrahydrofuran, and acetone were obtained from Chem-Supply and used as received. Milli-Q water with a resistivity of  $> 18$  M $\Omega$ ·cm was obtained from an in-line Millipore RiOs/Origin water purification system. Antibiotics (amoxicillin, ampicillin, azithromycin dihydrate, ceftriaxone disodium salt hemi (heptahydrate), ciprofloxacin hydrochloride, clarithromycin, colistin sodium methanesulfonate and doxycycline hydrochloride) were purchased from Sigma-Aldrich. Gentamicin sulfate was purchased from Enzo life sciences and tobramycin was purchased from Biogal.

**Characterizations.** <sup>1</sup>H Nuclear magnetic resonance (NMR) spectra were obtained using a Bruker AC300F spectrometer. Deuterated solvents D<sub>2</sub>O or CDCl<sub>3</sub> (obtained from Cambridge Isotope Laboratories) were used as reference solvents and samples with concentration of ca. 10-20 mg mL<sup>-1</sup> were prepared. The monomer composition of the polymers was calculated using the following equation  $f_{a,b/6} : f_{c/9} : f_{d/2}$  where  $f_{a,b}$ ,  $f_c$ , and  $f_d$  correspond to the integrals of the characteristic protons of 2-ethylhexyl acrylate (methyl -CH<sub>3</sub>- groups,  $\delta_H$  0.80-0.98 ppm), cationic monomer (*tert*-butyl -CH<sub>3</sub>- groups,  $\delta_H$  1.38-1.52 ppm) and OEGA (ester -CH<sub>2</sub>O- groups, 4.10-4.30 ppm), respectively (Figure S1, Supporting Information (SI)).

Gel permeation chromatography (GPC) analysis was performed using a Shimadzu liquid chromatography system equipped with a Shimadzu refractive index detector and two MIX C columns (Polymer Lab) operating at 40 °C. Tetrahydrofuran was used as the eluent at a flow rate of 1 mL min<sup>-1</sup>. The system was calibrated with poly(methyl methacrylate) standards with molecular weights of 200 to 10<sup>6</sup> g mol<sup>-1</sup>.

Zeta-potential measurements were conducted using a Malvern Zetasizer Nano ZS apparatus equipped with a He-Ne laser operated at  $\lambda = 633$  nm and at a scattering angle of 173°. Samples were prepared at a concentration of ca. 2 mg mL<sup>-1</sup> where filtered Milli-Q water (using 0.45  $\mu$ m pore size filter) was used as the solvent to solubilize the polymer.

**Synthesis of cationic monomer.** Cationic monomer *tert*-butyl (4-acrylamidobutyl) carbamate was prepared in the same manner as reported previously.<sup>35</sup> Briefly, ethylenediamine (0.3 mol) was dissolved in chloroform (400 mL), followed by the dropwise addition of di-*tert*-butyl dicarbonate (0.03 mol in 100 mL) over 2 h at 0–5 °C. The reaction mixture was stirred overnight at 25 °C. White precipitates were filtered, and the organic phase was washed exhaustively with water using a separation funnel to remove excess diamines. The organic layer was then dehydrated over MgSO<sub>4</sub>, filtered, and dried using a rotary evaporation unit to yield a pale-yellow oil. Tetrahydrofuran (100 mL) was added to dissolve the intermediate product. Triethylamine (36 mmol) and acryloyl chloride (31.5 mmol) were added dropwise to the solution at 0–5 °C with N<sub>2</sub> bubbling. The contents were stirred at 25 °C for 1 h. The byproducts were filtered, and the solvent was removed in vacuo. The crude product was dissolved in chloroform (150 mL) and washed against brine (1 × 75 mL). The organic phase was stirred with MgSO<sub>4</sub> and basic Al<sub>2</sub>O<sub>3</sub> for 10 min, filtered, and concentrated in vacuo. The product was further purified by repeated precipitation steps in hexane to yield the *tert*-butyloxycarbonyl (Boc)-protected monomer as a fine white powder, which was dried in vacuo.

*tert*-Butyl (2-acrylamidoethyl) carbamate: <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>, 25 °C),  $\delta_{\text{H}}$  6.56 (br s, 1H, NH), 6.28 (dd,  $J$  = 17.1 Hz, 1.5 Hz, 1H, CHH=CH), 6.12 (dd,  $J$  = 17.1 Hz, 10.2 Hz, 1H, CHH=CH), 5.65 (dd,  $J$  = 10.2 Hz, 1.5 Hz, 1H, CHH=CH), 5.05 (br s, 1H, NH), 3.49–3.41 (m, 2H, CH<sub>2</sub>), 3.34–3.28 (m, 2H, CH<sub>2</sub>), 1.45 (s, 9H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>, 25 °C),  $\delta_{\text{C}}$  166.23, 157.50, 130.88, 126.30, 79.85, 41.05, 40.09, 28.35.

**Synthesis of amphiphilic ternary random copolymer (P).** The synthesis of amphiphilic ternary statistical copolymer proceeded in the same manner as reported previously.<sup>35</sup> Briefly, the RAFT agent benzyl dodecyl carbonotrithioate (11.6  $\mu$ mol), AIBN (4.6  $\mu$ mol), OEGA (350  $\mu$ mol), *tert*-butyl (4-acrylamidobutyl) carbamate (580  $\mu$ mol), and 2-ethylhexyl acrylate (230  $\mu$ mol) were dissolved in 1,4-dioxane (such that the total monomer concentration in solvent is 1 M). The solution was purged with N<sub>2</sub> for 20 min in an ice bath. The polymerization was conducted for 20 h at 70 °C and then quenched in an ice bath with exposing to air. The polymer was purified by precipitation in a hexane/diethyl ether (7:3) mixture thrice and subsequently dried in vacuo. The Boc-protected polymer produced monomodal molecular weight

distributions with dispersity ( $\mathcal{D}$ ) value of 1.3 and the number-averaged molecular weight ( $M_n$ ) of 17500 g mol<sup>-1</sup> as evidenced by GPC analysis (Figure S2, SI)

The Boc protecting groups were removed using TFA in the same manner as reported previously.<sup>35</sup> In general, the polymer solution in dichloromethane (ca. 10 wt % polymer) was treated with TFA (20 mol equivalent with respect to the Boc group) for 3 h at 25 °C. Boc- deprotected polymer was subsequently precipitated into diethyl ether/hexane (4:1). The precipitate was isolated by centrifugation, dissolved in methanol, and reprecipitated two more times. The polymer was then dried in vacuo and further purified by dialysis against water (Cellu-Sep 3500 MWCO). The aqueous solution was lyophilized to yield the Boc-deprotected polymer **P**.

**Minimum inhibitory concentration (MIC).** The MIC of polymer and selected antibiotics were determined via broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Briefly, a single colony was cultured in 10 mL of Mueller-Hinton broth (MHB) at 37 °C with shaking at 200 rpm overnight. Subsequently, a subculture was prepared from the overnight culture by diluting 1:100 in 10 mL MHB and allowed to grow to mid-log phase, then diluted to the appropriate concentration for the MIC test. A twofold dilution series of 100  $\mu$ L of polymers solution in MHB were added into 96-well microplates followed by the addition of 100  $\mu$ L of the subculture suspension. The final concentration of bacteria in each well was ca.  $5 \times 10^5$  cells mL<sup>-1</sup>. The plates were incubated at 37 °C for 20 h, and the absorbance at 600 nm was measured with a microtiter plate reader (FLUOstar Omega, BMG Labtech). MIC values were defined as the lowest concentration of sample that showed no visible growth and inhibited cell growth by more than 90%. Positive controls without polymer and negative controls without bacteria were included. All assays included two replicates and were repeated in at least three independent experiments.

**Checkerboard assay.** The checkerboard assay was performed in 96-well cell culture plates (Costar, Corning®) containing polymer and antibiotic in MHB. Concentration gradients of polymer and selected antibiotics were prepared in the horizontal and vertical direction in a 10  $\times$  8 layout, respectively. Bacterial suspensions were prepared in the same manner as abovementioned for MIC test and added to the plates. Positive and negative controls, without antimicrobial agent and bacteria respectively, were also included.

1 The plates were incubated at 37 °C for 20 h, and the absorbance at 600 nm was recorded subsequently. The  
2 MICs of individual polymer and antibiotics were computed from the corresponding column or row which  
3 contains only one component, while the remaining columns and rows were screened for fractional inhibitory  
4 concentration index (FICI). The FICI values were calculated as follows:  
5  
6  
7  
8

9  
10  
11 
$$FICI = \frac{MIC_{A \text{ in combination}}}{MIC_A} + \frac{MIC_{B \text{ in combination}}}{MIC_B}$$
 Equation 1  
12  
13

14 The FICI data was interpreted as follows:  $\leq 0.5$ , synergistic effect;  $0.5 < FICI < 1$ , indifference; and  $\geq 1$ ,  
15 antagonistic. All experiments were repeated in at least two independent experiments.  
16  
17

18  
19 **Killing studies.** To evaluate the bactericidal activity of selected compounds and combinations, *P.*  
20 *aeruginosa* PAO1 and 6294 biofilms were grown. A single colony of PAO1 or PA6294 was cultured  
21 overnight in 10 mL of Luria Bertani medium (LB 10) at 37 °C with shaking at 200 rpm. The overnight  
22 culture was diluted 1:200 in freshly prepared M9 minimal medium containing 48 mM Na<sub>2</sub>HPO<sub>4</sub>, 22 mM  
23 KH<sub>2</sub>PO<sub>4</sub>, 9 mM NaCl, 19 mM NH<sub>4</sub>Cl, pH 7.0, supplemented with 2 mM MgSO<sub>4</sub>, 100 µM CaCl<sub>2</sub> and 20 mM  
24 glucose. The bacterial suspension was then aliquoted (1 mL per well) into tissue-culture treated 24-well  
25 plates (Costar, Corning®). The plates were incubated at 37 °C with shaking at 180 rpm in an orbital shaker  
26 that does not stop agitation when the door is opened (model OM11, Ratek, Boronia, Australia) and the  
27 biofilm cultures were allowed to grow for 6.5 h without any disruption. The compounds were then added to  
28 the wells and the plates were incubated for 20 min. After treatment, the planktonic and biofilm viability  
29 analysis were determined by a drop plate method. For planktonic analysis, free-floating cells in the biofilm  
30 supernatant were serially diluted in sterile PBS and plated onto LB agar. For biofilm analysis, cells attached  
31 on the interior surfaces of the well (surface area 4.5 cm<sup>2</sup>) were washed twice with sterile PBS to remove  
32 loosely attached bacteria, before being resuspended and homogenized in PBS by incubating in an  
33 ultrasonication bath (150 W, 40 kHz; Unisonics, Australia) for 20 min. Resuspended biofilm cells were then  
34 serially diluted and plated onto LB agar. Planktonic and biofilm colonies were counted and CFU was  
35 calculated after 24 h incubation at 37 °C. All assays included two replicates and were repeated in at least  
36 three independent experiments.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Antimicrobial Resistance Studies.** To investigate the resistance development in *Pseudomonas aeruginosa* PAO1, bacterial suspensions at exponential phase ( $\sim 10^7$  cells mL<sup>-1</sup>) were subjected to sequential passaging in the presence of selected compounds at sub-inhibitory concentrations (i.e.,  $1/4 \times$  MIC,  $1/2 \times$  MIC,  $1 \times$  MIC and  $2 \times$  MIC) for 21 days. Cells were incubated at 37 °C and passaged at 24 h intervals. After incubation, the cultures were checked for growth. Cultures from the second highest concentrations that allow growth ( $OD_{600} \geq 2.00$ ) were diluted to an  $OD_{600}$  of 0.01 per milliliter in fresh MHB containing  $1/4 \times$  MIC,  $1/2 \times$  MIC,  $1 \times$  MIC and  $2 \times$  MIC of selected compound. Assays were performed with two independent experiments.

## Results and Discussion

The ability of synthetic antimicrobial polymers to combat MDR bacteria provides the key motivation for us to investigate their efficacy in combination therapy along with traditional antibiotics. For this, we used an antimicrobial polymer in the form of an amphiphilic random ternary copolymer (**P**) that was developed by our group.<sup>35</sup> Large quantities of polymer can be made in a facile manner via a controlled radical polymerization technique, termed reversible addition–fragmentation chain transfer (RAFT) polymerization (**Scheme 1**).<sup>42, 43</sup> This polymer was meticulously designed to have optimal antimicrobial activity and biocompatibility. It contains 30 repeat units of biocompatible oligoethylene glycol to impart low-fouling properties, 20 repeat units of hydrophobic ethylhexyl groups to induce membrane disruption, and 50 repeat units of primary amino groups to establish electrostatic interactions with bacterial membrane.<sup>35, 36</sup>


**Scheme 1.** Synthesis of antimicrobial polymer, **P**, which is an amphiphilic random ternary copolymer, via reversible addition–fragmentation chain transfer (RAFT) polymerization.




To assess the potential synergistic effect between **P** and commercially available antibiotics, their interactions were evaluated using checkerboard assay. **Figure 2** shows the chemical structure and mode of action of ten common antibiotics used in this study. These antibiotics were selected based on their ability to act on different mechanisms, such as targeting protein synthesis (doxycycline, clarithromycin, azithromycin, gentamycin and tobramycin), cell wall biosynthesis (ampicillin, amoxicillin, ceftriaxone), cell wall integrity (colistin) and DNA synthesis (ciprofloxacin) in bacteria.

## Inhibition of protein synthesis


## Macrolides

**Clarithromycin**

Reversibly bind to the 50S subunit of ribosome and block the peptide exit tunnel


**Azithromycin**

## Tetracyclines


**Doxycycline**

Reversibly binds to the 30S subunit of ribosome and inhibit aminoacyl-tRNA binding to ribosome

## Aminoglycosides



**Gentamicin**

Bind to the 30S subunit of ribosome and cause tRNA mismatching

**Tobramycin**


## Inhibition of cell wall synthesis

## Penicillins

**Ampicillin****Amoxicillin**


Interfere with the biosynthesis of the cell wall through inhibition of cross-linking of peptidoglycan units

## Cephalosporins

**Ceftriaxone**

## Inhibition of DNA synthesis


## Fluoroquinolones

**Ciprofloxacin**

Targets DNA topoisomerase II and interferes with nucleic acid replication

## Cell Wall Disruption

## Polymyxins

**Colistin**

Causes physical cell membrane disruption through destabilization of lipopolysaccharide molecules

**Figure 2.** Chemical structure and reported mode of action of the antibiotics used in this work.<sup>44, 45</sup>

1 Checkerboard plots of tested combinations against two Gram-negative bacteria *Pseudomonas aeruginosa*  
2 PAO1 and *Escherichia coli* K12 are represented in **Figures S3 and S4 (SI)**, Gram-positive bacteria were not  
3 included in this study as the antimicrobial activity of **P** is better against Gram-negative bacteria.<sup>37</sup> This assay  
4 is conducted to evaluate the bacteriostatic activity of proposed combinations. Minimum inhibitory  
5 concentrations (MICs) of the used antimicrobial agents alone and in combination, and fractional inhibitory  
6 concentration indexes (FICIs) of the tested combinations against *P. aeruginosa* PAO1 and *E. coli* K12 are  
7 shown in Tables S1 and S2 (SI). It is worthwhile noting that FICI is a parameter commonly used to  
8 determine the synergism/antagonism of compounds in combination therapy. Although both tested bacteria  
9 were susceptible to all selected antibiotics, only doxycycline (**D**) and colistin methanesulfonate (**C**) showed  
10 synergy ( $FICI \leq 0.5$ ) with **P**. Notably, indifference ( $0.5 < FICI < 1$ ) was the most common interaction  
11 between **P** and antibiotics, but none of the combinations demonstrated antagonism interaction ( $FICI \geq 1$ )  
12 against the tested bacteria strains. It is noteworthy that clarithromycin showed synergy with **P** exclusively  
13 against *P. aeruginosa* PAO1.


14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 The combination of **P** and **D** (**PD**) yielded synergistic activity against *P. aeruginosa* PAO1 and *E. coli*  
32 K12 with FICI values of 0.38–0.50 and 0.50, respectively. Co-administration of these antimicrobial agents  
33 resulted in at least a 4-fold decrease in MIC values of **P** and **D** against *P. aeruginosa* PAO1 (Table S1 and  
34 S2, SI). Meanwhile, **P** and **C** combination (**PC**) demonstrated stronger synergy against *P. aeruginosa* PAO1  
35 ( $FICI = 0.38$ ) compared to *E. coli* K12 ( $FICI = 0.50$ ). Based on these results, both combinations  
36 demonstrated slight species-specific activity, where slightly greater synergy was observed against *P.*  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2

probable when drugs that act on a similar mechanism are used in combination.<sup>22, 31</sup> Given that both **P** and **C** predominantly act on the same mechanism of membrane wall disruption, this might be the reason behind the observed synergistic activity in **PC**.

Following these results, the potency of the synergistic combinations (**PD** and **PC**) were evaluated against four more *P. aeruginosa* strains including PA ATCC 27853, an invasive strain isolated from microbial keratitis (PA 6294)<sup>46</sup> and two MDR strains (PA32 and PA37) also isolated from cases of microbial keratitis<sup>47, 48</sup> via the checkerboard method (Figure 3 and Table 1).

**PD** and **PC** exhibited synergism against all tested *P. aeruginosa* strains. The greatest synergistic effect was found against MDR strains PA32 and PA37 for both **PD** and **PC**. The strongest synergistic activities with FICI values of 0.28 and 0.38 against PA32, and 0.25 and 0.31 against PA37 were observed for **PD** and **PC** respectively (Table 1). As an example, although PA32 showed resistance toward both **P** and **D**, we observed a 4- to 8-fold and 4- to 32-fold decrease in the MIC values of **P** and **D** respectively, when **PD** was used. **P** at a sub-MIC level as low as 16  $\mu\text{g mL}^{-1}$  (MIC = 128  $\mu\text{g mL}^{-1}$ ) was able to reduce the MIC of **D** from 128  $\mu\text{g mL}^{-1}$  to 4  $\mu\text{g mL}^{-1}$  (Table 1) when used in combination.




**Figure 3.** Checkerboard microdilution assay between **P** and **D** (a-e), and **P** and **C** (f-j) against *P. aeruginosa* PAO1, PA6294, PA ATCC 27853, PA32 and PA37. Bacterial growth, quantified by average OD<sub>600</sub>, is illustrated as a linear gradient from white to green and burgundy where darker colors represent less growth inhibition. Yellow and red bullets represent MIC values for **P** and antibiotic, respectively. Blue bullets indicate concentrations exhibiting synergistic interaction. The data are representative of a minimum of two biological replicates.

**Table 1.** Checkerboard assay results indicating the synergistic activity of **P with D** and **C** and against five *P. aeruginosa* strains including PAO1, PA6294, PA ATCC 27853, PA32 and PA37. All the combinations showed moderate to high synergism (FICI ≤ 0.5)

|               | MIC (μg mL <sup>-1</sup> ) |     |                |    | FICI | MIC (μg mL <sup>-1</sup> ) |    |                |   | FICI |
|---------------|----------------------------|-----|----------------|----|------|----------------------------|----|----------------|---|------|
|               | Alone                      |     | In Combination |    |      | Alone                      |    | In Combination |   |      |
|               | P                          | D   | P              | D  |      | P                          | C  | P              | C |      |
|               |                            |     |                |    |      |                            |    |                |   |      |
| PAO1          | 32                         | 8   | 8              | 1  | 0.38 | 32                         | 16 | 4              | 4 | 0.38 |
|               |                            |     | 8              | 2  | 0.50 |                            |    | 8              | 2 | 0.38 |
| PA6294        | 64                         | 8   | 16             | 1  | 0.38 | 64                         | 8  | 8              | 2 | 0.38 |
|               |                            |     | 16             | 2  | 0.50 |                            |    | 16             | 1 | 0.38 |
| PA ATCC 27853 | 32                         | 16  | 8              | 4  | 0.50 | 64                         | 32 | 16             | 8 | 0.50 |
| PA32          | 128                        | 128 | 32             | 4  | 0.28 | 64                         | 16 | 16             | 2 | 0.38 |
|               |                            |     | 32             | 8  | 0.31 |                            |    | 16             | 4 | 0.50 |
|               |                            |     | 16             | 32 | 0.38 |                            |    | -              | - | -    |
| PA37          | 128                        | 256 | 16             | 32 | 0.25 | 128                        | 16 | 32             | 1 | 0.31 |
|               |                            |     | 32             | 16 | 0.31 |                            |    | 32             | 2 | 0.38 |
|               |                            |     | -              | -  | -    |                            |    | 16             | 4 | 0.38 |

Subsequently, bactericidal and antibiofilm activity of **PD** and **PC** synergistic combinations were investigated. Colony-forming unit (CFU) analysis was used to assess the bactericidal activity of the combinations against both planktonic and biofilm bacteria. *P. aeruginosa* PAO1 biofilms were grown in cell culture media M9 for 6.5 h prior to incubation with selected compounds at different concentrations for 20 min.

First, the bactericidal activities of **PD** and **PC** at fixed **P** concentration of 128 µg mL<sup>-1</sup> and three antibiotic concentrations of 16, 32 and 64 µg mL<sup>-1</sup>, denoted as 128/16, 128/32 and 128/64 µg mL<sup>-1</sup>, were examined against PAO1. For comparison, individual **P** and antibiotics (**D** and **C**) were also tested (Figure 4a-d).



**Figure 4.** Bactericidal activity of individual components and combinations. Bactericidal activity of **P**, **D**, and **PD** on planktonic (a) and biofilm (b) *P. aeruginosa* PAO1. Bactericidal activity of **P**, **C**, and **PC** on planktonic (c) and biofilm (d) *P. aeruginosa* PAO1. Bactericidal activity of **P**, **D**, and **PD** on planktonic (e) and biofilm (f) *P. aeruginosa* 6294. All bactericidal activities were determined by colony-forming unit (CFU) analysis upon 20 min incubation. Data are representative of at least three independent experiments  $\pm$  SD. Two-way ANOVA test – asterisks indicate statistically significant difference of **PD** and **PC** vs **P** treatment ( $**p < 0.01$ ;  $***p < 0.001$ ;  $****p < 0.0001$ ; ns, non-significant ( $p > 0.01$ )).

For the planktonic cells, treatment with **P** at  $128 \mu\text{g mL}^{-1}$  for 20 min resulted in an average of  $3.3 \pm 0.24$   $\text{log}_{10}$  reduction in CFU compared to the untreated sample, while **D** and **C** did not cause any significant reduction in bacterial cell viability (Figure 4a, c and Table S3, SI). Both **PD** and **PC** exhibited bactericidal property against planktonic bacteria in a dose-dependent manner. Treatment with **PD** at concentrations of  $128/64$ ,  $128/32$  and  $128/16 \mu\text{g mL}^{-1}$  led to  $5.4 \pm 0.29$ ,  $5.3 \pm 0.61$  and  $4.8 \pm 0.48$   $\text{log}_{10}$  reductions in CFU, respectively, compared to the untreated sample. These results confirm the synergistic effect of **PD** in killing planktonic bacteria cells at the tested concentrations. **PC**, on the other hand, showed significant synergy only at  $128/64 \mu\text{g mL}^{-1}$  causing  $5.1 \pm 0.59$   $\text{log}_{10}$  reduction in CFU compared to the untreated sample.


Synergistic bactericidal activity was also observed against bacterial biofilm upon treatment with **PD** in the same dose-dependent manner (Figure 4b and Table S3, SI). We observed synergistic effect at the highest **D** concentration ( $128/64 \mu\text{g mL}^{-1}$ ), whereas it was non-significant at lower **D** concentrations ( $128/32$  and

128/16  $\mu\text{g mL}^{-1}$ ). Treatment with **PD** for 20 min at 128/64  $\mu\text{g mL}^{-1}$  resulted in  $5.5\pm0.43 \log_{10}$  reductions in CFU, compared to the untreated biofilm. However, the differences between the bactericidal activities of **P** and **PC** at all tested concentrations were non-significant based on ANOVA analysis (Figure 4d and Table S3, SI).

We then tested the bactericidal activity of **PD** against *P. aeruginosa* 6294. We observed synergy against planktonic PA6294 with  $6.2\pm0.10$ ,  $6.0\pm0.39$  and  $5.9\pm0.87 \log_{10}$  reductions in CFU compared to the untreated sample at treatment concentrations of 128/64, 128/32 and 128/16  $\mu\text{g mL}^{-1}$  respectively (Figure 4e and Table S3, SI). Interestingly, **PD** demonstrated a reverse dose-dependent trend against bacterial biofilm, where the lowest **D** concentration caused the highest reduction in CFU with a  $4.7\pm0.14 \log_{10}$  reduction in CFU at 128/16  $\mu\text{g mL}^{-1}$  compared to the untreated sample (Figure 4f and Table S3, SI).

The observed synergy between **P** and **D** in the killing assays might be caused by the bacteriostatic characteristic of **D**, where it can potentiate the bactericidal activity of **P** by restricting bacterial growth.

Next, an antimicrobial resistance study was conducted to investigate if **PD** can induce resistance in *P. aeruginosa* PAO1. **P** and **D** were also included as controls. For this, 20 serial passages of bacterial cells were done over a period of 21 days in the presence of sub-MIC levels of **P**, **D**, and **PD** (Figure 5). It is worthwhile noting that based on our previous work *P. aeruginosa* PAO1 could not develop resistance toward **C** over a period of 22 days,<sup>35</sup> therefore **PC** and **C** were not included in the resistance study.



**Figure 5.** Resistance development monitoring in *P. aeruginosa* PAO1 in the presence of sub-MIC levels of **P**, **D** and **PD**. The y-axis indicates the changes in MICs of the compounds over a period of 21 days as compared



to the first day (0<sup>th</sup> passage). Note that the bacteria cultures from 20<sup>th</sup> passage were used in supplementary MIC test.

*P. aeruginosa* PAO1 developed resistance toward **D** rapidly, where the MIC increased 32 times the original value and plateaued after six days. **P**, on the other hand, triggered minor resistance in *P. aeruginosa* which is in accordance with our previous study.<sup>35</sup> The MIC value changed between 1 × MIC and 2 × MIC over the test period and finally reached 4 × MIC. This behaviour is attributed to the membrane disruption mechanism of **P** which minimizes the likelihood of resistance development in bacteria. The MIC for **PD** was less volatile, fluctuating between 1 × MIC and 2 × MIC but not exceeding 2 × MIC during the test period, which shows the potency of **PD** in suppressing resistance development in bacteria.

A supplementary antimicrobial activity test was subsequently performed against the obtained modified strains from the resistance study to evaluate their susceptibility to further treatments. For this, bacteria cells were derived from the 20<sup>th</sup> passage of all three treatments (**PAO1-20-D**, **PAO1-20-P** and **PAO1-20-PD**) and subjected to **P**, **D** and **PD**. Table 2 shows the MIC values of **P**, **D** and **PD** against unmodified and modified strains of *P. aeruginosa* PAO1.

**Table 2.** Supplementary antimicrobial activity test showing the susceptibility of modified strains of *P. aeruginosa* PAO1 (obtained from the 20<sup>th</sup> passage of resistant study, see Figure 5) to **P**, **D** and **PD**.

| Treatment | MIC (µg mL <sup>-1</sup> ) |           |           |            |
|-----------|----------------------------|-----------|-----------|------------|
|           | PAO1                       | PAO1-20-D | PAO1-20-P | PAO1-20-PD |
| <b>D</b>  | 8                          | 256       | 8-16      | 32         |
| <b>P</b>  | 32                         | 32        | 128       | 32         |
| <b>PD</b> | 8/2                        | 16/4      | 32/8      | 16/4       |

For modified **D** strain (**PAO1-20-D**), we observed no change in the MIC value of **P**, while there was a two-fold increase in the MIC value of **PD** which might be the result of acquired resistance toward **D**.

Although showing a minor resistance to **PD** treatment, **PD** is a potent treatment for **PAO1-20-D** by lowering the required **D** dose by 64 times compared to individual **D**. Not surprisingly, an increase in the MIC value for **PD** was observed against **PAO1-20-P**, where 4 × MIC was needed to effectively combat the modified **P**

1 strain. **D**, on the other hand, retained the same MIC value against **PAO1-20-P**. In the case of **PAO1-20-PD**,  
2 even after 20 passages in the presence of **PD**, no resistance was observed toward **P**, whereas  $4 \times$  MIC was  
3 required to inhibit the bacterial growth using **D**. However, this level of resistance to **D** is considered minimal  
4 compared to exclusively **D** treated PAO1(**PAO1-20-D**).  
5  
6  
7  
8  
9

10 These observations suggest that: (i) the acquisition of resistance toward either **P** or **D** is hindered through  
11 co-administration, and (ii) when **PD** is used against modified strains (**PAO1-20-P** and **PAO1-20-D**), **P** is  
12 more efficient in reviving PAO1 susceptibility to **D**, rather than vice versa.  
13  
14  
15  
16  
17  
18  
19

20 **Conclusion**  
21

22  
23 In summary, we investigated the efficacy of combination therapy involving our synthetic antimicrobial  
24 polymer and commercially available antibiotics. Polymer-drug interactions were studied via checkerboard  
25 assay where two synergistic combinations, containing doxycycline and colistin antibiotics, were detected.  
26 Synergistic combinations demonstrated bacteriostatic activity against Gram-negative bacteria such as *P.*  
27 *aeruginosa* and *E. coli*, where the greatest synergism was observed against MDR *P. aeruginosa* strains. A  
28 synergistic effect in planktonic and biofilm killing activity was also achieved using the combination of  
29 antimicrobial polymer and doxycycline, which suggests that doxycycline, even though as a bacteriostatic  
30 antibiotic, could potentiate the killing activity of polymer. In addition, serial passaging revealed that this  
31 synergistic combination can significantly hinder the generation of resistant mutant strains compared to  
32 individual compounds. This study shed valuable information on the potential use of synthetic antimicrobial  
33 polymers in combination with specific antibiotics in an effort to combat MDR bacteria.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 **ASSOCIATED CONTENT**  
53

54 **Supporting Information**  
55

56 The Supporting Information is available free of charge on the ACS Publications website. Polymer  
57 characterization, including GPC and NMR, checkerboard microdilution assay, Figures S1-S4 and Tables S1-  
58 S3.  
59  
60

## AUTHOR INFORMATION

### Corresponding Authors

\*(E.H.H.W.) E-mail: [edgar.wong@unsw.edu.au](mailto:edgar.wong@unsw.edu.au)

\*(C.B.) E-mail: [cboyer@unsw.edu.au](mailto:cboyer@unsw.edu.au)

### Author Contributions

The manuscript was written through contribution of all authors. All authors have given approval to the final version of the manuscript.

**Notes:** The authors declare no competing financial interest.

### Acknowledgments

This work was supported by UNSW Australia and the Australian Research Council via the 2016 UNSW Vice Chancellor's Research Fellowship (E.H.H.W.), Future Fellowship (FT120100096, C.B.), respectively. R.N.Z. acknowledges the receipt of an Australian Government Research Training Program (RTP) Scholarship. We also acknowledge the facilities and technical assistance provided by the Mark Wainwright Analytical Centre at UNSW Australia via the Nuclear Magnetic Resonance Facility.

### References

- (1) Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, L. B., Stelling, J., Struelens, M. J., Vatopoulos, A., Weber, J. T., and Monnet, D. L. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 18, 268-281, DOI 10.1111/j.1469-0691.2011.03570.

- (2) Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., and Bartlett, J. (2009) Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* 48, 1-12, DOI 10.1086/595011.
- (3) Levy, S. B., and Marshall, B. (2004) Antibacterial resistance worldwide: causes, challenges and responses. *Nat. Med.* 10, S122-S129, DOI 10.1038/nm1145.
- (4) Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., and Daszak, P. (2008) Global trends in emerging infectious diseases. *Nature.* 451, 990-993, DOI 10.1038/nature06536.
- (5) Sadrearhami, Z., Nguyen, T.-K., Namivandi-Zangeneh, R., Jung, K., Wong, E. H. H., and Boyer, C. (2018) Recent advances in nitric oxide delivery for antimicrobial applications using polymer-based systems. *J. Mater. Chem. B.* 6, 2945-2959, DOI 10.1039/C8TB00299A.
- (6) Serpi, M., Ferrari, V., and Pertusati, F. (2016) Nucleoside Derived Antibiotics to Fight Microbial Drug Resistance: New Utilities for an Established Class of Drugs? *J. Med. Chem.* 59, 10343-10382, DOI 10.1021/acs.jmedchem.6b00325.
- (7) Davies, J., and Davies, D. (2010) Origins and Evolution of Antibiotic Resistance. *Microbiol. Mol. Biol. Rev.* 74, 417-433, DOI 10.1128/mmbr.00016-10.
- (8) Costerton, J. W., Stewart, P. S., and Greenberg, E. P. (1999) Bacterial Biofilms: A Common Cause of Persistent Infections. *Science.* 284, 1318-1322, DOI 10.1126/science.284.5418.1318.
- (9) D'Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., Golding, G. B., Poinar, H. N., and Wright, G. D. (2011) Antibiotic resistance is ancient. *Nature.* 477, 457-461, DOI 10.1038/nature10388.
- (10) Tam, V. H., Rogers, C. A., Chang, K.-T., Weston, J. S., Caeiro, J.-P., and Garey, K. W. (2010) Impact of Multidrug-Resistant *Pseudomonas aeruginosa* Bacteremia on Patient Outcomes. *Antimicrob. Agents Chemother.* 54, 3717-3722, DOI 10.1128/aac.00207-10.
- (11) Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance. *Nature.* 406, 775-781, DOI 10.1038/35021219.
- (12) Petchiappan, A., and Chatterji, D. (2017) Antibiotic Resistance: Current Perspectives. *ACS Omega.* 2, 7400-7409, DOI 10.1021/acsomega.7b01368.

- (13) Fischbach, M. A., and Walsh, C. T. (2009) Antibiotics for Emerging Pathogens. *Science*. 325, 1089-1093, DOI 10.1126/science.1176667.
- (14) González-Bello, C. (2017) Antibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics. *Bioorg. Med. Chem. Lett.* 27, 4221-4228, DOI 10.1016/j.bmcl.2017.08.027.
- (15) Wright, G. D. (2016) Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. *Trends Microbiol.* 24, 862-871, DOI 10.1016/j.tim.2016.06.009.
- (16) Kenawy, E.-R., Worley, S. D., and Broughton, R. (2007) The Chemistry and Applications of Antimicrobial Polymers: A State-of-the-Art Review. *Biomacromolecules*. 8, 1359-1384, DOI 10.1021/bm061150q.
- (17) Timofeeva, L., and Kleshcheva, N. (2011) Antimicrobial polymers: mechanism of action, factors of activity, and applications. *Appl. Microbiol. Biotechnol.* 89, 475-492, DOI 10.1007/s00253-010-2920-9.
- (18) Lam, S. J., Wong, E. H. H., Boyer, C., and Qiao, G. G. (2018) Antimicrobial polymeric nanoparticles. *Prog. Polym. Sci.* 76, 40-64, DOI 10.1016/j.progpolymsci.2017.07.007.
- (19) Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. *Nature*. 415, 389-395, DOI 10.1038/415389a.
- (20) Matsuzaki, K. (2009) Control of cell selectivity of antimicrobial peptides. *Biochim. Biophys. Acta*. 1788, 1687-1692, DOI 10.1016/j.bbamem.2008.09.013.
- (21) Jenssen, H., Hamill, P., and Hancock, R. E. W. (2006) Peptide Antimicrobial Agents. *Clin. Microbiol. Rev.* 19, 491-511, DOI 10.1128/cmr.00056-05.
- (22) Fischbach, M. A. (2011) Combination therapies for combating antimicrobial resistance. *Curr. Opin. Microbiol.* 14, 519-523, DOI 10.1016/j.mib.2011.08.003.
- (23) Cottarel, G., and Wierzbowski, J. (2007) Combination drugs, an emerging option for antibacterial therapy. *Trends Biotechnol.* 25, 547-555, DOI 10.1016/j.tibtech.2007.09.004.
- (24) Paul, M., Lador, A., Grozinsky-Glasberg, S., and Leibovici, L. (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database Syst Rev.* 1-177, DOI 10.1002/14651858.CD003344.pub3.
- (25) Bassetti, M., Repetto, E., Righi, E., Boni, S., Diverio, M., Molinari, M. P., Mussap, M., Artioli, S., Ansaldi, F., Durando, P., Orengo, G., Bobbio Pallavicini, F., and Viscoli, C. (2008) Colistin and

- 1 rifampicin in the treatment of multidrug-resistant *Acinetobacter baumannii* infections. *J. Antimicrob.*  
2 *Chemother.* 61, 417-420, DOI 10.1093/jac/dkm509.
- 3  
4  
5 (26) Tamma, P. D., Cosgrove, S. E., and Maragakis, L. L. (2012) Combination Therapy for Treatment of  
6  
7 Infections with Gram-Negative Bacteria. *Clin. Microbiol. Rev.* 25, 450-470, DOI 10.1128/cmr.05041-11.  
8  
9 (27) Ejim, L., Farha, M. A., Falconer, S. B., Wildenhain, J., Coombes, B. K., Tyers, M., Brown, E. D., and  
10  
11 Wright, G. D. (2011) Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy.  
12  
13 *Nat. Chem. Biol.* 7, 348-350, DOI 10.1038/nchembio.559.
- 14  
15  
16 (28) Schneider, E. K., Reyes-Ortega, F., Velkov, T., and Li, J. (2017) Antibiotic–non-antibiotic  
17  
18 combinations for combating extremely drug-resistant Gram-negative ‘superbugs’. *Essays Biochem.* 61,  
19  
20 115-125, DOI 10.1042/ebc20160058.
- 21  
22  
23 (29) Mouton, J. W. (1999) Combination therapy as a tool to prevent emergence of bacterial resistance.  
24  
25 *Infection.* 27, S24-S28, DOI 10.1007/bf02561666.
- 26  
27  
28 (30) Elphick, H. E., and Scott, A. (2016) Single versus combination intravenous anti-pseudomonal antibiotic  
29  
30 therapy for people with cystic fibrosis. *Cochrane Database Syst Rev.* 1-41, DOI  
31  
32 10.1002/14651858.CD002007.pub4.
- 33  
34  
35 (31) Brochado, A. R., Telzerow, A., Bobonis, J., Banzhaf, M., Mateus, A., Selkrig, J., Huth, E., Bassler, S.,  
36  
37 Zamarreño Beas, J., Zietek, M., Ng, N., Foerster, S., Ezraty, B., Py, B., Barras, F., Savitski, M. M., Bork,  
38  
39 P., Göttig, S., and Typas, A. (2018) Species-specific activity of antibacterial drug combinations. *Nature.*  
40  
41 559, 259-263, DOI 10.1038/s41586-018-0278-9.
- 42  
43  
44 (32) Tian, J., Zhang, J., Yang, J., Du, L., Geng, H., and Cheng, Y. (2017) Conjugated Polymers Act  
45  
46 Synergistically with Antibiotics to Combat Bacterial Drug Resistance. *ACS Appl. Mater. Interfaces.* 9,  
47  
48 18512-18520, DOI 10.1021/acsami.7b03906.
- 49  
50  
51 (33) Ng, V. W. L., Ke, X., Lee, A. L. Z., Hedrick, J. L., and Yang, Y. Y. (2013) Synergistic Co-Delivery of  
52  
53 Membrane-Disrupting Polymers with Commercial Antibiotics against Highly Opportunistic Bacteria.  
54  
55 *Adv. Mater.* 25, 6730-6736, DOI 10.1002/adma.201302952.
- 56  
57  
58 (34) Khalil, H., Chen, T., Riffon, R., Wang, R., and Wang, Z. (2008) Synergy between polyethylenimine  
59  
60 and different families of antibiotics against a resistant clinical isolate of *Pseudomonas aeruginosa*.  
*Antimicrob. Agents Chemother.* 52, 1635-1641, DOI 10.1128/AAC.01071-07.

- (35) Nguyen, T.-K., Lam, S. J., Ho, K. K. K., Kumar, N., Qiao, G. G., Egan, S., Boyer, C., and Wong, E. H. (2017) Rational Design of Single-Chain Polymeric Nanoparticles That Kill Planktonic and Biofilm Bacteria. *ACS Infect. Dis.* 3, 237-248, DOI 10.1021/acsinfecdis.6b00203.
- (36) Namivandi-Zangeneh, R., Kwan, R. J., Nguyen, T.-K., Yeow, J., Byrne, F. L., Oehlers, S. H., Wong, E. H. H., and Boyer, C. (2018) The effects of polymer topology and chain length on the antimicrobial activity and hemocompatibility of amphiphilic ternary copolymers. *Polym. Chem.* 9, 1735-1744, DOI 10.1039/C7PY01069A.
- (37) Judzewitsch, P. R., Nguyen, T.-K., Shanmugam, S., Wong, E. H. H., and Boyer, C. (2018) Towards Sequence-Controlled Antimicrobial Polymers: Effect of Polymer Block Order on Antimicrobial Activity. *Angew. Chem., Int. Ed.* 57, 4559-4564, DOI 10.1002/anie.201713036.
- (38) Nguyen, T.-K., Selvanayagam, R., Ho, K. K. K., Chen, R., Kutty, S. K., Rice, S. A., Kumar, N., Barraud, N., Duong, H. T. T., and Boyer, C. (2016) Co-delivery of nitric oxide and antibiotic using polymeric nanoparticles. *Chem. Sci.* 7, 1016-1027, DOI 10.1039/C5SC02769A.
- (39) Namivandi-Zangeneh, R., Sadrearhami, Z., Bagheri, A., Sauvage-Nguyen, M., Ho, K. K. K., Kumar, N., Wong, E. H. H., and Boyer, C. (2018) Nitric Oxide-Loaded Antimicrobial Polymer for the Synergistic Eradication of Bacterial Biofilm. *ACS Macro Lett.* 7, 592-597, DOI 10.1021/acsmacrolett.8b00190.
- (40) Oo, T. Z., Cole, N., Garthwaite, L., Willcox, M. D. P., and Zhu, H. (2010) Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. *J. Antimicrob. Chemother.* 65, 1243-1251, DOI 10.1093/jac/dkq106.
- (41) Willcox, M. D. P., Hume, E. B., Schubert, T. L., and Kumar, N. (2017) Treatment of Staphylococcus Aureus with Antibiotic and Quorum-Sensing Inhibitor Combinations Reduces Severity of Keratitis. *J Ocular Biol.* 5, 1-5.
- (42) Moad, G., Rizzardo, E., and Thang, S. H. (2013) RAFT Polymerization and Some of its Applications. *Chem. Asian J.* 8, 1634-1644, DOI 10.1002/asia.201300262.
- (43) Boyer, C., Bulmus, V., Davis, T. P., Ladmiral, V., Liu, J., and Perrier, S. (2009) Bioapplications of RAFT Polymerization. *Chem. Rev.* 109, 5402-5436, DOI 10.1021/cr9001403.

- (44) Rossiter, S. E., Fletcher, M. H., and Wuest, W. M. (2017) Natural Products as Platforms To Overcome Antibiotic Resistance. *Chem. Rev.* *117*, 12415-12474, DOI 10.1021/acs.chemrev.7b00283.
- (45) Kohanski, M. A., Dwyer, D. J., and Collins, J. J. (2010) How antibiotics kill bacteria: from targets to networks. *Nat. Rev. Microbiol.* *8*, 423-435, DOI 10.1038/nrmicro2333.
- (46) Dutta, D., Vijay, A. K., Kumar, N., and Willcox, M. D. P. (2016) Melimine-Coated Antimicrobial Contact Lenses Reduce Microbial Keratitis in an Animal Model. *Investig. Ophthalmol. Vis. Sci.* *57*, 5616-5624, DOI 10.1167/iovs.16-19882.
- (47) Dutta, D., Cole, N., Kumar, N., and Willcox, M. D. P. (2013) Broad Spectrum Antimicrobial Activity of Melimine Covalently Bound to Contact Lenses. *Investig. Ophthalmol. Vis. Sci.* *54*, 175-182, DOI 10.1167/iovs.12-10989.
- (48) Subedi, D., Vijay, A. K., Kohli, G. S., Rice, S. A., and Willcox, M. (2018) Association between possession of ExoU and antibiotic resistance in *Pseudomonas aeruginosa*. *PLoS One.* *13*, 1-14, DOI 10.1371/journal.pone.0204936.



For Table of Contents Use Only

